Evidence map›Paper›PMID 39795243›Full record

ReviewMolecules (Basel, Switzerland)2025

Genistein Implications in Radiotherapy: Kill Two Birds with One Stone.

Xiongxiong Liu, Tong Zheng, Yanyu Bao, Ping Li, Ting Zhao, Yan Liu, Hui Wang, Chao Sun

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Targeting glutathione metabolism for tumor radiosensitization (Review).International journal of molecular medicine · 2026
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiongxiong LiuInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China.ORCID 0000-0002-1048-2758
Tong ZhengInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China.
Yanyu BaoInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China.
Ping LiInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China.
Ting ZhaoInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China.
Yan LiuSchool of Medical Imaging, Binzhou Medical University, Yantai 264003, China.ORCID 0000-0002-2067-4569
Hui WangInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China.
Chao SunInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China.ORCID 0000-0002-9046-3142

Funding

"Hundred People Program" of Chinese Academy of Sciences 2024-05the Longyuan Youth Talent Program of Gansu Province 2022-5the Natural Science Foundation of Gansu Province 23JRRA677, 22JR5RA119
6 · The paper itself

Abstract

More than 70% of cancer patients receive radiotherapy during their treatment, with consequent various side effects on normal cells due to high ionizing radiation doses despite tumor shrinkage. To date, many radioprotectors and radiosensitizers have been investigated in preclinical studies, but their use has been hampered by the high toxicity to normal cells or poor tumor radiosensitization effects. Genistein is a naturally occurring isoflavone found in soy products. It selectively sensitizes tumor cells to radiation while protecting normal cells from radiation-induced damage, thus improving the efficacy of radiotherapy and consequent therapeutic outcomes while reducing adverse effects. Genistein protects normal cells by its potent antioxidant effect that reduces oxidative stress and mitigates radiation-induced apoptosis and inflammation. Conversely, genistein increases the radiosensitivity of tumor cells through specific mechanisms such as the inhibition of DNA repair, the arrest of the cell cycle in the G

Indexed as

GenisteinNeoplasmsRadiation-Protective AgentsRadiation-Sensitizing AgentsAnimalsApoptosisHumansOxidative StressRadiation ToleranceReactive Oxygen SpeciesGenisteinRadiation-Protective AgentsRadiation-Sensitizing AgentsReactive Oxygen Speciescancer treatmentgenisteinradioprotectionradiosensitizationradiotherapy

Identifiers

PMID39795243
PMCPMC11723059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.